Lv4
424 积分 2022-08-03 加入
Achievable but elusive: LLDAS and DORIS remission in clinical trials of belimumab
10小时前
已完结
Allogeneic CD19-targeted CAR-T therapy in patients with severe myositis and systemic sclerosis
1天前
已完结
Design, synthesis and antitumor activity of a novel FGFR2-selective degrader to overcome resistance of the FGFR2V564F gatekeeper mutation based on a pan-FGFR inhibitor
19天前
已完结
Synthesis and identification of a selective FGFR2 degrader with potent antiproliferative effects in gastric cancer
19天前
已完结
Synthesis and identification of a selective FGFR2 degrader with potent antiproliferative effects in gastric cancer
20天前
已完结
Discovery of BW710 as a Potent, Selective and Orally Bioavailable Fibroblast Growth Factor Receptor 2 (FGFR2) Inhibitor
20天前
已完结
P0636 Impact of obefazimod treatment on histologic and combined histologic and endoscopic outcomes in patients with moderately to severely active ulcerative colitis: results from the Phase 2b open-label maintenance study
1个月前
已完结
Phase 2 Trial of Anti-TL1A Monoclonal Antibody Tulisokibart for Ulcerative Colitis
1个月前
已完结
P2X7 Receptor in Kidney Disease
1个月前
已关闭
Advances and challenges in kidney fibrosis therapeutics
1个月前
已完结
皖公网安备34019202002308
